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OBJECTIVE—To determine the role of glucagon action in the
metabolic phenotype of untreated insulin deﬁciency.
RESEARCH DESIGN AND METHODS—We compared perti-
nent clinical and metabolic parameters in glucagon receptor-null
(Gcgr
2/2) mice and wild-type (Gcgr
+/+) controls after equivalent
destruction of b-cells. We used a double dose of streptozotocin to
maximize b-cell destruction.
RESULTS—Gcgr
+/+ mice became hyperglycemic (.500 mg/dL),
hyperketonemic, polyuric, and cachectic and had to be killed after
6 weeks. Despite comparable b-cell destruction in Gcgr
2/2 mice,
none of the foregoing clinical or laboratory manifestations of di-
abetes appeared. There was marked a-cell hyperplasia and hyper-
glucagonemia (;1,200 pg/mL), but hepatic phosphorylated cAMP
response element binding protein and phosphoenolpyruvate car-
boxykinase mRNA were profoundly reduced compared with
Gcgr
+/+ mice with diabetes—evidence that glucagon action had
been effectively blocked. Fasting glucose levels and oral and in-
traperitoneal glucose tolerance tests were normal. Both fasting
and nonfasting free fatty acid levels and nonfasting b-hydroxy
butyrate levels were lower.
CONCLUSIONS—We conclude that blocking glucagon action
prevents the deadly metabolic and clinical derangements of type
1 diabetic mice. Diabetes 60:391–397, 2011
T
he development of a radioimmunoassay for glu-
cagon (1) established the hormonal status of this
peptide (2), originally considered to be a con-
taminant of the insulin extraction process. Glu-
cagon was immunocytochemically localized to pancreatic
a-cells (3) and shown to be secreted in response to in-
creased glucose need, as in starvation and exercise (4). By
1973, it was recognized that a-cell function was grossly
abnormal in diabetes, particularly in type 1 diabetes (5).
Here, b-cells are largely replaced by a-cells, and, without
the inhibitory action of insulin, their secretion of glucagon
is unrestrained, and glucagon action on the liver is un-
opposed. The result is a lethal hypercatabolic state. In
1973, the discovery of somatostatin (6), a potent inhibitor
of glucagon secretion, made it possible to demonstrate the
essential role of glucagon in the metabolic phenotype of
type 1 diabetes (7–10).
Those studies led to a search for a therapeutic sup-
pressor of diabetic hyperglucagonemia or blocker of its
action on the liver. In the 37 years since the discovery of
somatostatin, only one other potent glucagon-suppressing
substance, leptin, has been identiﬁed (11,12). By contrast,
inactivators of glucagon have been less elusive. High afﬁnity
antiglucagon antibodies have beneﬁted diabetic animals
(13), as have a variety of molecules that block binding of
glucagon to the glucagon receptor and/or block its signaling
(14–18). Diabetic mice with glucagon receptor knockout
(19) or mice treated with Gcgr antisense oligonucleotide
similarly beneﬁt from the elimination of glucagon action
(20,21). Although all of the foregoing reports demonstrate
that abrogation of glucagon action reduces hepatic over-
production of glucose, a potential therapeutic asset in di-
abetes management, none of the foregoing diabetic models
studied thus far have been totally insulin-deﬁcient, as in
type 1 diabetes. In type 1 diabetes, islets are virtually devoid
of b-cells, and are largely made up of hyperplastic a-cells. In
contrast to normal a-cells, which are restrained by the high
local concentrations of intraislet insulin (22), type 1 diabetic
a-cells are unregulated, which results in inappropriate
hyperglucagonemia (5). Moreover, with no insulin to oppose
the hepatic actions of the hyperglucagonemia, unrestrained
glycogenolysis, gluconeogenesis, ketogenesis, and hyper-
catabolism lead rapidly to ketoacidosis, cachexia, coma,
and death.
An essential role of hyperglucagonemia in the patho-
genesis of this lethal syndrome has long been suspected
but never fully proven. Recent studies of adenovirally in-
duced hyperleptinemia in type 1 diabetic mice (12) in-
dicate that glucagon suppression normalizes all metabolic
parameters for more than a month despite a total absence
of insulin. More recently, the same antidiabetic efﬁcacy
has been demonstrated with recombinant leptin (11,23).
However, leptin-induced actions other than suppression of
glucagon, such as increased insulin-like growth factor-1
(IGF-1) (12) and insulin-like growth factor-binding protein-2
(IGFBP-2) (23), may have contributed. To obtain un-
assailable proof that glucagon action by itself causes the
lethal consequences of insulin deﬁciency, we induced in-
sulin deﬁciency in glucagon receptor-null (Gcgr
2/2) mice.
Gcgr
2/2 mice were treated with streptozotocin (STZ), the
most commonly used b-cytotoxins in rodents, in an effort
to achieve complete insulin deﬁciency in the complete
absence of glucagon activity. We compared the metabolic
phenotype of complete b-cell destruction in mice in which
glucagon action had been transgenically abrogated by
knockout of the glucagon receptor (24). Because Gcgr
2/2
mice are resistant to STZ-induced b-cell destruction (24), it
was necessary to use a double dose of the b-cell poison
STZ. Despite b-cell destruction equivalent to the wild-type
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ORIGINAL ARTICLE(Gcgr
+/+) mice, Gcgr
2/2 remained free of all manifestations
of insulin deﬁciency.
RESEARCH DESIGN AND METHODS
Male mice with global glucagon receptor knockout and wild-type mice (19)
were provided by M.J.C. They were housed in individual cages with constant
temperature and 12 h of light alternating with 12 h of darkness and fed Teklad
6% mouse/rat diet (Teklad, Madison, WI) with free access to water. The pro-
tocol was approved by the Institutional Animal Care and Research Advisory
Committee of the University of Texas Southwestern Medical Center and the
Institutional Animal Care and Use Committee at the North Texas Veterans
Administration Medical Center.
Chemical destruction of b-cells. b-cells were destroyed in 10- to 12-week-old
Gcgr
2/2 and Gcgr
+/+ mice with two intravenous injections of STZ (100 mg/kg
body weight followed in 7 days by 80 mg/kg). Food intake, body weight, and
blood glucose were measured weekly for 6 weeks.
Plasma measurements. Blood glucose levels were measured with a glucose
meter (Bayer Healthcare, Mishawka, IN). Plasma glucagon levels were mea-
sured using a Linco glucagon RIA kit (Linco Research, St. Charles, MO). Plasma
insulin levels were measured using a rat/mouse insulin ELISA kit (Crystal
Chem, Downers Grove, IL), and IGF-1 levels were measured using an IGF-1
ELISA kit (Immunodiagnostic Systems Ltd., Boldon, UK). Free fatty acids
(FFAs) were measured with a nonesteriﬁed fatty acid (NEFA) kit (Waco Pure
Chemical Industries, Osaka, Japan).
Oral glucose tolerance test. After a 16 h fast, glucose (2 g/kg) was admin-
istered by gavage to the Gcgr mice. Blood was taken at 0, 15, 30, 45, 60, 90, and
120 min intervals, and the blood glucose and plasma insulin were analyzed.
Immunoblotting. Livers were lysed in radioimmunoprecipitation (RIPA)
buffer (0.15mM NaCl/0.05mM TrisHCl, pH,7.2/1% Triton-X100/1% sodium
deoxycholate/0.1% SDS) with 10 mg/mL leupeptin and 10 mg/mL aprotinin.
Proteins were resolved by sulfate-polyacrylamide gel electrophoresis (SDS/
PAGE) and transferred to a membrane (GE Healthcare, Piscataway, NJ).
The blotted membrane was blocked in 1 3 Tris-buffered saline (TBS) con-
taining 0.1% tween 20 (TBST) and 5% nonfat dry milk for 1 h at room tem-
perature. After incubation with primary antibodies to cAMP-responsive
element binding (CREB) and phospho-CREB (P-CREB) (1:1000; Cell Signaling
Technology, Danvers, MA) or anti–g-tubulin at 4°C overnight, the membrane
was washed with TBST buffer. Membranes were incubated with goat anti-
rabbit or anti-mouse horseradish peroxidase–conjugated IgG for 1 h. The
proteins were detected by using enhanced chemiluminescence detection system
(GE Healthcare).
Real-time quantitative PCR. Total RNA was extracted from the liver by
Trizol isolation method (Life Technologies, Rockville, MD). All PCR reactions
were performed in triplicate as previously described (25). The mRNA level was
calculated by using standard curve method. Primer sequences are shown in
Supplementary Table 1.
Amino acid analysis of livers. Amino acids were analyzed in liver homoge-
natesbytandemmassspectrometry(MS/MS).AllMSanalysesusedstable-isotope
dilutionwithinternalstandardsfromIsotec,CambridgeIsotopeLaboratories,and
CDN Isotopes.
Immunohistochemistry and b-cell mass measurement. The distal 20% of
pancreata dissected from adult mice were ﬁxed in Bouin’s solution (Sigma, St.
Louis, MO) and dehydrated prior to parafﬁn embedding. Five micrometer
contiguous parafﬁn sections were prepared on a Leica RM2155 rotary mi-
crotome for insulin and glucagon immunohistochemical staining, as previously
described (26). Morphometric analysis for insulin cells was performed
using Image-J image analysis software and particle analysis macro (Scion,
Frederick, MD). The area of insulin staining in three sections of pancreas from
4–6 animals, relative to total sectional area examined, was quantiﬁed by
monochromatic thresholding.
Statistical analysis. Results are reported as means 6 SEM. Statistical anal-
ysis of the data was performed with Student t test.
RESULTS
Assessing completeness of b-cell destruction by STZ.
Conarello et al. (24) reported that Gcgr
2/2 mice are re-
sistant to the b-cytotoxic action of STZ and without com-
plete destruction of b-cells, it would be impossible to
evaluate the beneﬁts of glucagon blockade in total insulin
deﬁciency states. Because increased b-cell survival in
Gcgr
2/2 mice could explain the lack of hyperglycemia in
response to a b-cytotoxin, we administered a double dose,
100 mg/kg of body weight of STZ, followed 7 days later
with an 80 mg/kg dose. We quantiﬁed the surviving b-cells
with STZ-treated Gcgr
+/+ mice by immunostaining for in-
sulin and glucagon. Morphometry of immunocytochemi-
cally stained insulin-positive cells revealed 90% b-cell
destruction in sections of pancreata from Gcgr
2/2 mice,
not signiﬁcantly different from the 94% destruction Gcgr
+/+
mice (Table 1). After STZ treatment, a-cell area of Gcgr
+/+
mice increased 10-fold. The a-cell area of Gcgr
2/2 mice
before STZ was almost 7-fold greater than that of un-
treated Gcgr
+/+ mice and after STZ it was 39-fold greater
(Table 1). Plasma insulin levels were reduced by 90% after
STZ in both groups (Table 1). Finally, the most sensitive
and speciﬁc indicator of b-cell activity, pancreatic pre-
proinsulin mRNA, was below the detectable range of
quantitative real-time PCR (qRT-PCR) in both Gcgr
+/+ and
Gcgr
/- mice treated with STZ (Table 1). These ﬁndings in-
dicate that the STZ-resistance of b-cells of Gcgr
2/2 mice
could be overcome by doubling the dose of the b-cytotoxin.
This made it possible to determine the role of diabetic
hyperglucagonemia on the phenotype of complete insulin
deﬁciency.
Completeness of glucagon inactivation. A second
prerequisite of the study was that glucagon be completely
inactivated. Plasma glucagon levels in Gcgr
2/2 mice were
;14-fold higher than in Gcgr
+/+ mice prior to STZ treat-
ment, conﬁrming the report of Gelling et al. (19), and
;16-fold higher after STZ treatment (Fig. 1A and B). To
assess the completeness of glucagon inactivation in the
Gcgr
2/2 mice, we compared the hepatic levels of P-CREB
(27), a key protein in its signal transduction pathway, with
those of wild-type controls. Given the marked hyper-
glucagonemia, hepatic P-CREB should be increased if any
functionally intact glucagon receptor was present in liver.
However, P-CREB could not be detected in livers of STZ-
diabetic Gcgr
2/2 mice (Fig. 1C). Total CREB protein was
also reduced. These results are consistent with those pre-
viously reported by Gelling et al. (19) that conﬁrm a com-
plete blockade of glucagon action in the liver of Gcgr
2/2
mice.
TABLE 1
Comparison residual insulin production in nonfasting Gcgr
+/+ and Gcgr
2/2 mice treated with STZ (n =6 )
Nondiabetic STZ-diabetic
Gcgr
+/+ Gcgr
2/2 STZ Gcgr
+/+ STZ Gcgr
2/2
b-cell area (mm
2) 23,279 6 5,614 15,760 6 1,413* 1,548 6 132 1,618 6 147
a-cell area (mm
2) 4,431 6 873 27,825 6 4,358 44,927 6 5.488 17,4081 6 26,103
Plasma insulin (ng/mL) 1.86 6 0.11 1.82 6 0.16 0.19 6 0.15 0.21 6 0.07
Preproinsulin (AU) 0.106 6 0.0081 0.215 6 0.0530 undetectable undetectable
Data are means 6 SEM. *P , 0.05. AU, arbitrary unit.
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type that developed rapidly in Gcgr
+/+ mice after the large
dose of STZ did not appear in Gcgr
2/2 mice treated with
the same STZ dose. Food intake rose in the Gcgr
+/+ di-
abetic mice from 4.5 g/d before the diabetes to 9.3 g/d after
STZ treatment but increased by only 3.0 g/d in the Gcgr
2/2
mice (Fig. 2A). The severe polyuria and polydipsia of
the Gcgr
+/+ mice did not occur in the STZ-treated Gcgr
2/2
mice (data not shown). The diabetic wild-type mice became
progressively sicker and had to be killed, whereas the
Gcgr
2/2 mice seemed to remain in their normal state of
health throughout the 6-week study despite the lack of
insulin and were apparently healthy when ﬁnally killed at
12 weeks after STZ.
Body weight of the mice before and 6 weeks after STZ
treatment appears in Fig. 2B.
Comparison of glucoregulatory parameters. All Gcgr
+/+
mice became severely hyperglycemic after treatment
with STZ, their fed and fasting blood glucose levels
approaching 500 mg/dL within a week after administration
of the STZ and increasing slightly thereafter. By contrast,
in the Gcgr
2/2 mice fed and fasting glucose levels after
STZ-treatment remained in a perfectly normal range
throughout the 6-week study and for at least 6 weeks
thereafter (Fig. 2C).
The ablation of glucagon action was expected to prevent
fasting hyperglycemia by reducing hepatic glucose pro-
duction but was not expected to improve the glucose tol-
erance test, which is generally considered to be, in large
part, an index of insulin-mediated glucose disposal. Sur-
prisingly, comparison of oral glucose tolerance of Gcgr
2/2
mice with and without STZ-induced destruction of b-cells
revealed normal curves in both groups. In other words, the
presence or absence of b-cells had no apparent effect on
the glucose curves of the Gcgr
2/2 mice, all of which were
well within normal limits (Fig. 2D). To exclude a differ-
ence in glucose absorption in the STZ-treated mice, we
performed intraperitoneal glucose tolerance tests in
Gcgr
2/2 mice with and without intact b-cells. Again, glu-
cose tolerance was normal in both groups (data not shown).
To determine if these unexpected results could be
explained by an increase in insulin from a few surviving
b-cells in the STZ-treated Gcgr
2/2 mice, we compared in-
sulin levels in the two groups. The STZ-treated Gcgr
2/2
mice exhibited no increase in insulin levels above the basal
value, whereas the insulin response of untreated knockout
mice rose to over 1.2 ng/mL—about the same as in normal
Gcgr
+/+ mice (Fig. 2E). Thus, insulin was not involved in
the normal glucose tolerance curves of Gcgr
2/2 mice.
IGF-1. To determine if an insulin-like growth factor might
have normalized glucose tolerance in the absence of in-
sulin, we measured fasting and postprandial IGF-1 levels.
In Gcgr
2/2 mice, fasting (65 6 27 vs. 256 6 48 ng/mL) and
nonfasting (130 6 20 vs. 303 6 23 ng/mL) IGF-1 levels were
signiﬁcantly below those of Gcgr
+/+ controls (P , 0.001). After
STZ treatment, in Gcgr
+/+ mice fasting IGF-1 levels varied
widely, averaging 284 6 90 vs. 140 6 10 ng/mL (not signiﬁ-
cant) in Gcgr
2/2 mice. Nonfasting IGF-1 levels, which could
not be detected in Gcgr
+/+ mice after STZ treatment, av-
eraged 109 6 17 ng/mL in STZ-treated Gcgr
2/2 mice. We
concluded that IGF-1 could not be the cause of the normal
glucose tolerance observed in the absence of both insulin
and glucagon action.
Comparison of FFAs and ketones. Fasting and FFA
levels were signiﬁcantly higher in normal Gcgr
2/2 mice
and Gcgr
+/+ controls. They were not suppressed by food in
either group (Fig. 3A). But both fasting and nonfasting
levels were signiﬁcantly lower in STZ-treated Gcgr
2/2
mice than in Gcgr
+/+ controls, consistent with a lipolytic
role for glucagon when insulin is very low. The plasma
b-hydroxybutyrate levels of Gcgr
2/2 mice were signiﬁ-
cantly below the elevated levels of STZ-treated Gcgr
+/+
controls (P , 0.001) (Fig. 3B), evidence that glucagon
action is required for ketogenesis, as proposed by Meier
et al. (28).
Phosphoenolpyruvate carboxykinase mRNA and
lactate levels in insulin-deﬁcient Gcgr
+/+ and Gcgr
2/2
mice. Uncontrolled insulin deﬁciency with hypergluca-
gonemia is characterized by increased gluconeogenesis as-
sociated with upregulation of the gluconeogenic enzyme,
phosphoenolpyruvate carboxykinase (PEPCK) (29,30). The
expression of this enzyme was therefore compared in Gcgr
+/+
and Gcgr
2/2 mice treated with STZ. Figure 4A shows the
expected increase in PEPCK mRNA in STZ-induced insulin
deﬁciency of Gcgr
+/+ mice. It was substantially reduced in
Gcgr
2/2 mice with STZ-induced insulin deﬁciency. This re-
duction was associated with a signiﬁcant increase in lactate,
a gluconeogenic precursor (Fig. 4B).
Amino acid levels in normal and insulin-deﬁcient
Gcgr
+/+ and Gcgr
2/2 mice. Boden et al. (31) have re-
ported that in normal subjects, hyperglucagonemia lowers
FIG. 1. A: Comparison of plasma glucagon levels in Gcgr
+/+ (■) and
Gcgr
2/2 (□) mice before and 6 weeks after STZ induction of b-cell
destruction. B: Glucagon in Gcgr
+/+ mice before and after STZ. C:
Representative immunoblots for CREB and P-CREB in livers of Gcgr
+/+
(■) and Gcgr
2/2 (□) mice after b-cell destruction by treatment with
STZ and in untreated controls (upper panel). The P-CREB/CREB ratio
in densitometric units in six Gcgr
+/+ (■) and six Gcgr
2/2 (□) mice after
b-cell destruction by treatment with STZ (lower panel).
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and that somatostatin-induced hypoglucagonemia has the
opposite effect. This prompted a metabolomic analysis of
amino acid proﬁles in the liver of both normal and insulin-
deﬁcient Gcgr
+/+ and Gcgr
2/2 mice (Table 2). Of the 16
amino acids measured, 9 were signiﬁcantly (P , 0.01) in-
creased in normal Gcgr
2/2 mice, but only 1 was elevated
in the STZ-treated insulin-deﬁcient Gcgr
2/2 mice. This
suggests that in the presence of normal insulin action,
glucagon action is required to prevent hepatic over-
accumulation of amino acids. When insulin is absent,
however, amino acid levels are relatively normal despite
lack of glucagon action.
DISCUSSION
The purpose of this study was to assess the role of the
hyperglucagonemia of total insulin deﬁciency in the lethal
catabolic consequences of the disease and to determine if
beneﬁcial effects of glucagon blockade are sufﬁcient and
safe enough to qualify as a potential therapeutic target in
human type 1 diabetes. This idea was proposed previously
(9,10) when somatostatin, the ﬁrst glucagon-suppressing
agent to be discovered (6), was found to prevent the acute
metabolic consequences of complete insulin lack (7,8).
The search for more practical suppressors or antagonists of
glucagon has been reenergized by the recent demonstration
that leptin can suppress diabetic hyperglucagonemia and
reverse the catabolic effects of complete insulin deﬁciency
for extended periods without apparent negative conse-
quences (11,12).
Although leptin is very effective in suppressing the
hyperglucagonemia and in reversing the metabolic mani-
festations of type 1 diabetes (11,12), the many other
actions of the adipocyte hormone make it impossible to
assume that suppression of glucagon by itself accounts for
the remarkable remission of all clinical and laboratory
manifestations of total insulin deﬁciency. The Gcgr
2/2
mice of Gelling et al. (24) provided an ideal model in which
to assess the immediate and longer-term beneﬁts and risks
of permanent elimination of glucagon action without other
actions of leptin unrelated to a-cell suppression, such as
food restriction and lipopenia. We were able to overcome
the previously reported resistance of Gcgr
2/2 mice to STZ
FIG. 2. A: Comparison of food intake in nondiabetic and STZ-treated Gcgr
+/+ (■) and Gcgr
2/2 (□) mice (n =6 ) .B: Comparison of body weight in
Gcgr
+/+ (■) and Gcgr
2/2 (□) before and after STZ induction of b-cell destruction. C: Comparisons of weekly nonfasting glucose levels in Gcgr
+/+
(●) and Gcgr
2/2 (□) after STZ-induced b-cell destruction, and overnight fasting glucose levels for Gcgr
+/+ (◆) and Gcgr
2/2 (◇) at the end of
the study (n =6 ) .D: Glucose values for oral glucose tolerance test (OGTT) (2 g/kg) performed after a 16-h fast in normal Gcgr
+/+ (●), Gcgr
2/2 (☐),
and STZ-treated Gcgr
2/2 (▲) mice (n =4 ) .E: Insulin levels for OGTT in normal Gcgr
+/+ (●), Gcgr
2/2 (☐), and STZ-treated Gcgr
2/2 (▲) mice
(n =4 ) .
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The b-cell destruction was as complete as in Gcgr
+/+ con-
trols, as evidenced by insulin assays of plasma, morpho-
metric comparison of pancreata for insulin-positive cells,
and qRT-PCR measurements of pancreatic preproinsulin
mRNA. This enabled an assessment of the effects of com-
plete elimination of glucagon action on the phenotype of
mice with total insulin deﬁciency.
Whereas all STZ-treated Gcgr
+/+ diabetic mice de-
veloped severe hyperglycemia, ketosis, and cachexia and
had to be killed for humane reasons ;30 days after in-
duction of diabetes, none of the insulin-deﬁcient Gcgr
2/2
mice developed any laboratory or clinical evidence of in-
sulin deﬁciency. Without exception, all STZ-treated Gcgr
2/2
mice appeared to be in a seemingly normal state of health
after the high dose of b-cytotoxin for at least 6 weeks. This
indicates that in the absence of glucagon action, insulin
deﬁciency in mice is a silent disorder without overt meta-
bolic or clinical manifestations, conﬁrming an earlier pre-
liminary observation in alloxan-treated mice (11). It also
suggests that glucagon suppression and/or antagonism may
be an extremely useful strategy to treat type 1 diabetes.
Other than fasting hypoglycemia, no signiﬁcant un-
desirable side effects of chronic blockade of glucagon
action were observed in this brief study. The marked a-cell
hyperplasia observed in Gcgr
2/2 pancreata (19) has led to
concerns that long-term glucagon receptor blockade could
FIG. 3. Comparison of fasting (▨) and nonfasting FFAs ( )( A)a n d
nonfasting b-OH butyrate levels (B) in STZ-treated Gcgr
+/+ (■)
and Gcgr
2/2 (□) mice and untreated controls (N =6 ) .
FIG. 4. Comparison of the ratio of PEPCK mRNA to 36B4 mRNA (A)a n d
plasma lactate levels (B)i nS T Z - t r e a t e dG c g r
+/+ (■)a n dG c g r
2/2 (□)
mice (N =6 ) .
TABLE 2
Liver amino acid levels (mM) in Gcgr
+/+ and Gcgr
2/2 mice
Normal Insulin deﬁciency
Gcgr
+/+ Gcgr
2/2 Gcgr
+/+ STZ Gcgr
2/2 STZ
Ala 246.10 6 51.36* 487.51 6 58.13* 359.31 6 123.78 327.45 6 42.27
Ser 145.86 6 4.77* 232.16 6 11.87*‡ 158.80 6 14.46 195.02 6 9.07‡
Glx 232.33 6 30.40* 554.39 6 62.84* 308.27 6 30.97† 526.43 6 23.00†
Pro 21.64 6 2.01* 30.59 6 1.32*‡ 30.54 6 5.47 25.79 6 0.100‡
Phe 20.01 6 0.91* 26.48 6 1.86* 26.88 6 4.59 30.42 6 1.44
Asx 53.63 6 8.73 * 115.39 6 10.78*‡ 51.81 6 4.62 55.76 6 4.95‡
Met 7.97 6 0.35* 12.33 6 0.64* 9.05 6 1.44 10.79 6 0.53
Arg 5.12 6 0.22* 15.19 6 2.25* 9.33 6 3.09 16.75 6 1.02
Orn 27.31 6 1.50* 73.22 6 43.79* 74.97 6 11.22 64.05 6 8.75
Data are means 6 SEM. Ala, alanine; Arg, arginine; Asx, aspartic acid and asparagines; Glx, glutamic acid and glutamine; Met, methionine;
Orn, ornithine; Phe, phenylalanine; Pro, proline; Ser, serine. Gcgr
+/+ vs. Gcgr
2/2;* P , 0.01. Gcgr
+/+ STZ vs. Gcgr
2/2 STZ; †P , 0.001. Gcgr
2/2 vs.
Gcgr
2/2 STZ; ‡P , 0.05.
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noma has not been observed in any of the Gcgr
2/2 mice
followed for up to 2 years (M.J.C., unpublished observa-
tion). Another theoretical hazard is the possibility of pre-
disposition to lactic acidosis based on the high blood
lactate levels in the Gcgr
2/2 mice. This is attributed to
reduced gluconeogenesis secondary to downregulation of
gluconeogenic genes. A third potential issue relates to the
role of glucagon in amino acid homeostasis. Amino acid
deﬁciency has been described in glucagonoma patients
(33,34), raising the possibility that Gcgr
2/2 mice might
have high amino acid levels, as reported by Boden et al.
(31) in humans in whom glucagon was suppressed by so-
matostatin. For this reason, we measured amino acid lev-
els in the livers of our normal and STZ-treated Gcgr
+/+ and
Gcgr
2/2 mice. As shown in Table 2, eight of the nine he-
patic amino acids measured were signiﬁcantly higher in
Gcgr
2/2 mice with intact b-cells than in normal Gcgr
+/+
mice. But no such differences occurred in STZ-treated
mice, suggesting that insulin action, when unopposed by
glucagon, was responsible for the increase.
By far the most surprising result of the study was the
normal glucose tolerance of insulin-deﬁcient Gcgr
2/2
mice. Currently, it is believed that it is the action of glu-
cose-stimulated insulin secretion on hepatic glucose bal-
ance and glucose uptake in muscle and fat that is the
essential determinant of glucose tolerance, with glucagon
suppression playing a supporting role. Here we ﬁnd that
both oral and intraperitoneal glucose tolerance in Gcgr
2/2
mice with b-cell destruction is as normal as in Gcgr
+/+mice
with intact islets, even though no rise in insulin was
detected in peripheral plasma of the former. Although we
did not measure portal vein insulin levels, the lack of
preproinsulin mRNA in the mice that received double-dose
STZ argues against undetected insulin reaching the liver.
The presence of residual granules in STZ-treated pancreata
does not necessarily signify a residual insulin source be-
cause insulin granules may persist in apoptotic b-cells or
in macrophages after all functioning b-cells have been
destroyed. Certainly in wild-type mice, neither the “re-
sidual” insulin in the pancreas nor the low levels of
“plasma insulin” were able to prevent a ketoacidotic death.
The lack of preproinsulin mRNA detectable by qRT-PCR,
which is far more sensitive and speciﬁc than either of the
immunologic techniques, suggests that the STZ-treated
mice were unable to produce insulin.
It seemed possible that the insulin-like responses were
caused by an increase in a hormone with insulinometic
activity. But neither leptin (not shown) (11) nor IGF-1 rose
signiﬁcantly in response to the glucose challenge. Alter-
natively, the elevated glucagon-like peptide 1 levels might
have increased muscle glucose uptake (32).
Recent studies by Meyer et al. (35) indicate that in
normal humans 90% of ingested glucose is taken up by
liver, muscle, brain, and kidney, and hepatic glucose re-
lease declines 82%. Except for the brain, red cells, and
possibly the kidney, glucose uptake is considered to be
insulin-mediated. To account for the perfectly normal
glucose tolerance in insulin-deﬁcient mice with congenital
lack of glucagon action, one can posit that insulin action
during glucose absorption is largely directed toward
overcoming the hepatic actions of glucagon during the
preglucose fast. In this case, if glucagon action on the liver
is absent, there is little, if anything, for insulin to do be-
cause the liver is already in a permanent storage mode.
Therefore, when the liver has never experienced the action
of glucagon, as in the Gcgr
2/2 mice, glucose disposition
without insulin is no different than when both hormones
are normally active (36). It should also be noted that
fasting and fed FFA levels (Fig. 3A) were both lower in
insulin-deﬁcient Gcgr
2/2 mice than in insulin-deﬁcient
Gcgr
+/+ mice, suggesting that, at least when unopposed by
insulin, glucagon may have lipolytic action in adipocytes,
as it does in hepatocytes.
Finally, a persistent but fallacious argument against an
essential role of glucagon in diabetes is the occurrence of
diabetes in totally depancreatized humans and animals. It
is not widely appreciated that when totally depancreatized
animals or humans are deprived of insulin, there is an in-
creased production of glucagon from extrapancreatic
a-cells (37) in the stomach and upper small bowel (38–43).
Suppression of the extrapancreatic hyperglucagonemia
restores hyperglycemia to normal (44).
Taken together these ﬁndings indicate in mice that type
1 diabetes can be converted into an asymptomatic, benign,
noncatabolic, insulin-independent disorder by elimination
of glucagon action. These studies support the clinical
utility of the development of potent Gcgr antagonists and/
or glucagon suppressors capable of eliminating the lethal
glucagon-dependent component of type 1 diabetes (45).
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